(NASDAQ: RGEN) Repligen's forecast annual revenue growth rate of 12.94% is forecast to beat the US Medical Instruments & Supplies industry's average forecast revenue growth rate of 8.51%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.84%.
Repligen's revenue in 2025 is $650,429,000.On average, 7 Wall Street analysts forecast RGEN's revenue for 2025 to be $39,937,700,452, with the lowest RGEN revenue forecast at $39,738,306,630, and the highest RGEN revenue forecast at $40,142,824,950. On average, 7 Wall Street analysts forecast RGEN's revenue for 2026 to be $45,935,808,208, with the lowest RGEN revenue forecast at $44,334,084,210, and the highest RGEN revenue forecast at $47,311,788,510.
In 2027, RGEN is forecast to generate $56,012,303,376 in revenue, with the lowest revenue forecast at $56,012,303,376 and the highest revenue forecast at $56,012,303,376.